Research analysts covering Burning Rock Biotech.
Recent press releases and 8-K filings for BNR.
Burning Rock Biotech Limited Reports Third Quarter 2025 Financial Results
BNR
Earnings
New Projects/Investments
Demand Weakening
- Burning Rock Biotech Limited reported total revenues of RMB131.6 million (US$18.5 million) for the three months ended September 30, 2025, marking a 2.3% increase from the same period in 2024.
- The company's net loss significantly improved to RMB16.8 million (US$2.4 million) for Q3 2025, compared to a net loss of RMB35.7 million for the same period in 2024.
- Revenue from pharma research and development services increased by 68.6% to RMB42.0 million (US$5.9 million) in Q3 2025, while in-hospital business revenue decreased by 17.1% and central laboratory business revenue decreased by 7.9%.
- Operating expenses decreased by 11.9% to RMB115.0 million (US$16.2 million) for the three months ended September 30, 2025, primarily due to decreases in amortized share-based compensation, budget control measures, and headcount reduction.
- In September 2025, Burning Rock received Manufacturing and Marketing Approval from Japan's Ministry of Health, Labour and Welfare for its OncoGuide® OncoScreen® Plus CDx System as a companion diagnostic for AstraZeneca's capivasertib.
Nov 20, 2025, 11:05 AM
Quarterly earnings call transcripts for Burning Rock Biotech.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more